Clinical Trials in Pittsburgh

Showing 201-220 of 16,007 trials

Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design

NCT02128906

The goal of this clinical research study is to learn which chemotherapy combination may be more effective in treating locally advanced head and neck squamous cell carcinoma (HNSCC). The side effects of these combinations will also be studied. This study treatment consists of intensity-modulated radiation therapy (IMRT) and concurrent chemotherapy. For study chemotherapy, patients will be randomized between cisplatin or the combination of docetaxel and cetuximab. Subjects will be stratified depending on HPV status and the presence of ERCC-1 \[4F9\] in the tumor prior to randomization. The study will evaluate cisplatin vs. docetaxel-cetuximab in the overall population, and test which radiation and chemotherapy combination works best in relationship to how much ERCC-1 \[4F9\] is expressed in a tumor.

Squamous Cell Carcinoma

Christopher Wilke120 participantsStarted Dec 2013

Pittsburgh, Pennsylvania, United States

COMPLETEDPhase 1< 1 mile

A Study of MK-8527 in Healthy Lactating Female Participants (MK-8527-009)

NCT06580587

The goal of this study is to learn how MK-8527 moves through the healthy person's body over time. Researchers will measure for the amount of MK-8527 in breast milk that the baby will receive at many time points.

HealthyHIV Pre-exposure Prophylaxis

Merck Sharp & Dohme LLC13 participantsStarted Apr 2025

Springfield, Missouri, United States • Pittsburgh, Pennsylvania, United States

RECRUITINGNA115 miles

Study of an Intrathecal Port and Catheter System for Subjects With Spinal Muscular Atrophy

NCT05866419

The primary objective of the clinical investigation is to demonstrate successful clinical use of the ThecaFlex DRx™ System in delivering nusinersen in subjects with spinal muscular atrophy (SMA). All enrolled subjects will undergo implantation of the investigational device (ThecaFlex DRx™ System) and will be followed for 12 months after receiving the implant. The 12-month data will be used to assess the primary endpoint support a Pre-Market Approval (PMA) application.

Spinal Muscular AtrophySpine DeformityScoliosis

Alcyone Therapeutics, Inc90 participantsStarted Nov 2023

Phoenix, Arizona, United States • Orange, California, United States • Palo Alto, California, United States +18 more locations

Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design

A Study of MK-8527 in Healthy Lactating Female Participants (MK-8527-009)

Study of an Intrathecal Port and Catheter System for Subjects With Spinal Muscular Atrophy

Find Trials by Condition in Pittsburgh

A Study With a Initial Treatment Period Followed by a Randomized-withdrawal Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE (WILLOW LTE)

Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

COMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomide

Expanded Access to Cyclic Irrigation in Patients Undergoing Exchange Arthroplasty

Testing the Addition of an Anti-cancer Drug, SNDX-5613, to the Standard Chemotherapy Treatment (Daunorubicin and Cytarabine) for Newly Diagnosed Patients With Acute Myeloid Leukemia That Has Changes in NPM1 or MLL/KMT2A Gene

A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjögren's Syndrome

An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.

Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)

Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia

Study of GS-9911 With or Without Antibody Treatment for Adults With Solid Tumors

PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors

Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma

Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

ITIL-306 in Advanced Solid Tumors

A Study to Test Different Doses of BI 3923948 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors)